List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1962009/publications.pdf Version: 2024-02-01

		81434	116156
188	5,664	41	66
papers	citations	h-index	g-index
191	191	191	5584
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Clinical value of early assessment of hyperfibrinolysis by rotational thromboelastometry during postpartum hemorrhage for the prediction of severity of bleeding: A multicenter prospective cohort study in the Netherlands. Acta Obstetricia Et Gynecologica Scandinavica, 2022, 101, 145-152.	1.3	9
2	Association between cardiovascular risk factors and intracranial hemorrhage in patients with acute leukemia. European Journal of Haematology, 2022, 108, 310-318.	1.1	0
3	Nationwide confidential enquiries into maternal deaths because of obstetric hemorrhage in the Netherlands between 2006 and 2019. Acta Obstetricia Et Gynecologica Scandinavica, 2022, 101, 450-460.	1.3	5
4	Social participation is reduced in type 3 Von Willebrand disease patients and in patients with a severe bleeding phenotype. Haemophilia, 2022, 28, 278-285.	1.0	1
5	Desmopressin response depends on the presence and type of genetic variants in patients with type 1 and type 2 von Willebrand disease. Blood Advances, 2022, 6, 5317-5326.	2.5	2
6	Best timing of tranexamic acid administration for bleeding after trauma or childbirth remains to be established. BMJ Evidence-Based Medicine, 2021, 26, 153-154.	1.7	0
7	Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001–2018. Journal of Thrombosis and Haemostasis, 2021, 19, 645-653.	1.9	48
8	Thrombocytopenia and the effect of platelet transfusions on the occurrence of intracranial hemorrhage in patients with acute leukemia – a nested case-control study. Annals of Hematology, 2021, 100, 261-271.	0.8	8
9	A total blood volume or more transfused during pregnancy or after childbirth: Individual patient data from six international population-based observational studies. PLoS ONE, 2021, 16, e0244933.	1.1	3
10	Von Willebrand Factor Multimer Densitometric Analysis: Validation of the Clinical Accuracy and Clinical Implications in Von Willebrand Disease. HemaSphere, 2021, 5, e542.	1.2	5
11	Reduction of antiâ€Kâ€mediated hemolytic disease of newborns after the introduction of a matched transfusion policy: A nationâ€wide policy change evaluation study in the Netherlands. Transfusion, 2021, 61, 713-721.	0.8	10
12	Major differences in clinical presentation, diagnosis and management of men and women with autosomal inherited bleeding disorders. EClinicalMedicine, 2021, 32, 100726.	3.2	30
13	Cardiovascular risk factors among adult patients with haemophilia. International Journal of Hematology, 2021, 113, 884-892.	0.7	6
14	Patientâ€relevant health outcomes for hemophilia care: Development of an international standard outcomes set. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12488.	1.0	20
15	Clinical value of early viscoelastometric pointâ€ofâ€care testing during postpartum hemorrhage for the prediction of severity of bleeding: A multicenter prospective cohort study in the Netherlands. Acta Obstetricia Et Gynecologica Scandinavica, 2021, 100, 1656-1664.	1.3	14
16	Risk factors for antibody formation in children with hemophilia: methodological aspects and clinical characteristics of the HEMFIL cohort study. Blood Coagulation and Fibrinolysis, 2021, 32, 443-450.	0.5	2
17	Expected individual benefit of prophylactic platelet transfusions in hematoâ€oncology patients based on bleeding risks. Transfusion, 2021, 61, 2578-2587.	0.8	2
18	Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial. Lancet Haematology,the, 2021, 8, e492-e502.	2.2	9

#	Article	IF	CITATIONS
19	Back to base pairs: What is the genetic risk for red bloodcell alloimmunization?. Blood Reviews, 2021, 48, 100794.	2.8	6
20	Treatmentâ€related risk factors for inhibitor development in nonâ€severe hemophilia A after 50 cumulative exposure days: A caseâ€control study. Journal of Thrombosis and Haemostasis, 2021, 19, 2171-2181.	1.9	8
21	Health and treatment outcomes of patients with hemophilia in the Netherlands, 1972–2019. Journal of Thrombosis and Haemostasis, 2021, 19, 2394-2406.	1.9	21
22	Incidence and mortality rates of intracranial hemorrhage in hemophilia: a systematic review and meta-analysis. Blood, 2021, 138, 2853-2873.	0.6	23
23	The effect of extended c, E and K matching in females under 45 years of age on the incidence of transfusionâ€induced red blood cell alloimmunisation. British Journal of Haematology, 2021, 195, 604-611.	1.2	6
24	Validation of PROMIS Profileâ $\in 29$ in adults with hemophilia in the Netherlands. Journal of Thrombosis and Haemostasis, 2021, 19, 2687-2701.	1.9	16
25	Hepatitis C virus in hemophilia: Healthâ€related quality of life after successful treatment in the sixth Hemophilia in the Netherlands study. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12616.	1.0	3
26	Variation in red cell transfusion practice in the intensive care unit – An international survey. Journal of Critical Care, 2020, 55, 140-144.	1.0	2
27	Patient Perspectives on Novel Treatments in Haemophilia: A Qualitative Study. Patient, 2020, 13, 201-210.	1.1	28
28	Donor sex and recipient outcomes. ISBT Science Series, 2020, 15, 142-150.	1.1	2
29	The factor VIII treatment history of nonâ€severe hemophilia A. Journal of Thrombosis and Haemostasis, 2020, 18, 3203-3210.	1.9	15
30	Evening aspirin intake results in higher levels of platelet inhibition and a reduction in reticulated platelets - a window of opportunity for patients with cardiovascular disease?. Platelets, 2020, 32, 1-7.	1.1	3
31	Prevalence and Incidence of Non-neutralizing Antibodies in Congenital Hemophilia A— A Systematic Review and Meta-Analysis. Frontiers in Immunology, 2020, 11, 563.	2.2	12
32	Transition from fresh frozen plasma to solvent/detergent plasma in the Netherlands: comparing clinical use and transfusion reaction risks. Haematologica, 2020, 105, 1158-1165.	1.7	10
33	Product type and the risk of inhibitor development in nonsevere haemophilia A patients: a case‒control study. British Journal of Haematology, 2020, 189, 1182-1191.	1.2	3
34	Risk factors for bleeding in haemato-oncology patients—a nested case–control study: The BITE study protocol (Bleeding In Thrombocytopenia Explained). BMJ Open, 2020, 10, e034710.	0.8	2
35	The Added Value of Lactate and Lactate Clearance in Prediction of In-Hospital Mortality in Critically III Patients With Sepsis. , 2020, 2, e0087.		15
36	Study protocol and pilot results of an observational cohort study evaluating effect of red blood cell transfusion on oxygenation and mitochondrial oxygen tension in critically ill patients with anaemia: the INsufficient Oxygenation in the Intensive Care Unit (INOX ICU-2) study. BMJ Open, 2020, 10, e036351.	0.8	3

#	Article	IF	CITATIONS
37	Semiautomatic VWF Multimer Densitometric Analysis: Validation of the Clinical Accuracy and Clinical Implications in Von Willebrand Disease. Blood, 2020, 136, 15-16.	0.6	0
38	Comparison of outcome between intrauterine balloon tamponade and uterine artery embolization in the management of persistent postpartum hemorrhage: A propensity scoreâ€matched cohort study. Acta Obstetricia Et Gynecologica Scandinavica, 2019, 98, 1473-1482.	1.3	7
39	Patientâ€centred care in haemophilia: Patient perspectives on visualization and participation in decisionâ€making. Haemophilia, 2019, 25, 938-945.	1.0	11
40	Effect of storage of platelet concentrates in PASâ€B, PASâ€C, or plasma on transfusion reactions. Transfusion, 2019, 59, 3140-3145.	0.8	9
41	Determinants of transfusion decisions in the ICU: haemoglobin concentration, what else? – a retrospective cohort study. Vox Sanguinis, 2019, 114, 816-825.	0.7	2
42	Women receiving massive transfusion due to postpartum hemorrhage: A comparison over time between two nationwide cohort studies. Acta Obstetricia Et Gynecologica Scandinavica, 2019, 98, 795-804.	1.3	20
43	Predicting anaemia and transfusion dependency in severe alloimmune haemolytic disease of the fetus and newborn in the first 3Âmonths after birth. British Journal of Haematology, 2019, 186, 565-573.	1.2	14
44	Predictive value of a bleeding score for postpartum hemorrhage. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 277-284.	1.0	4
45	BMI is an important determinant of VWF and FVIII levels and bleeding phenotype in patients with von Willebrand disease. American Journal of Hematology, 2019, 94, E201-E205.	2.0	15
46	Dynamic prediction of bleeding risk in thrombocytopenic preterm neonates. Haematologica, 2019, 104, 2300-2306.	1.7	16
47	Mortality of patients with haemophilia in Brazil: First report. Haemophilia, 2019, 25, e146-e152.	1.0	24
48	Fluid resuscitation during persistent postpartum haemorrhage and maternal outcome: A nationwide cohort study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2019, 235, 49-56.	0.5	17
49	Preterm neonates benefit from low prophylactic platelet transfusion threshold despite varying risk of bleeding or death. Blood, 2019, 134, 2354-2360.	0.6	41
50	Association of Timing of Plasma Transfusion With Adverse Maternal Outcomes in Women With Persistent Postpartum Hemorrhage. JAMA Network Open, 2019, 2, e1915628.	2.8	18
51	Inhibitor incidence in haemophilia A under exclusive use of a thirdâ€generation recombinant factor <scp>VIII</scp> concentrate: results of the <scp>HEMFIL</scp> Cohort Study. British Journal of Haematology, 2019, 186, 152-155.	1.2	5
52	Sports participation and physical activity in patients with von Willebrand disease. Haemophilia, 2019, 25, 101-108.	1.0	14
53	Are thrombocytopenia and platelet transfusions associated with major bleeding in preterm neonates? A systematic review. Blood Reviews, 2019, 36, 1-9.	2.8	27
54	Treatment and outcomes of fetal/neonatal alloimmune thrombocytopenia: a nationwide cohort study in newly detected cases. British Journal of Haematology, 2019, 184, 1026-1029.	1.2	8

#	Article	IF	CITATIONS
55	Genetic Association Studies of Red Blood Cell Transfusion Related Alloimmunization: A Systematic Review and Meta-Analysis. Blood, 2019, 134, 2459-2459.	0.6	1
56	Variation in red cell transfusion decisions in the intensive care unit – a nationwide survey in the Netherlands. Vox Sanguinis, 2018, 113, 378-385.	0.7	5
57	FactorÂVIII products and inhibitor development in previously treated patients with severe or moderately severe hemophiliaÂA: a systematic review. Journal of Thrombosis and Haemostasis, 2018, 16, 1055-1068.	1.9	25
58	Transfusion reactions after transfusion of platelets stored in PASâ€B, PASâ€C, or plasma: a nationwide comparison. Transfusion, 2018, 58, 1021-1027.	0.8	22
59	Comparing transfusion reaction risks for various plasma products – an analysis of 7Âyears of ISTARE haemovigilance data. British Journal of Haematology, 2018, 180, 727-734.	1.2	19
60	Influence of pre-analytical time and temperature conditions on serum thromboxane B 2 levels. Thrombosis Research, 2018, 163, 1-5.	0.8	5
61	Desmopressin in moderate hemophilia A patients: a treatment worth considering. Haematologica, 2018, 103, 550-557.	1.7	23
62	Ever-Pregnant Female Blood Donors and Mortality Risk in Male Recipients—Reply. JAMA - Journal of the American Medical Association, 2018, 319, 1048.	3.8	3
63	Personalization of medicine requires better observational evidence. Clinical Epidemiology, 2018, Volume 10, 1391-1399.	1.5	3
64	Clinically relevant differences between assays for von Willebrand factor activity. Journal of Thrombosis and Haemostasis, 2018, 16, 2413-2424.	1.9	26
65	The identification of cases of major hemorrhage during hospitalization in patients with acute leukemia using routinely recorded healthcare data. PLoS ONE, 2018, 13, e0200655.	1.1	6
66	Association between fluid management and dilutional coagulopathy in severe postpartum haemorrhage: a nationwide retrospective cohort study. BMC Pregnancy and Childbirth, 2018, 18, 398.	0.9	24
67	Coagulation parameters during the course of severe postpartum hemorrhage: a nationwide retrospective cohort study. Blood Advances, 2018, 2, 2433-2442.	2.5	35
68	Postponing Early intrauterine Transfusion with Intravenous immunoglobulin Treatment; the PETIT study on severe hemolytic disease of the fetus and newborn. American Journal of Obstetrics and Gynecology, 2018, 219, 291.e1-291.e9.	0.7	38
69	Defining patient value in haemophilia care. Haemophilia, 2018, 24, 516-518.	1.0	1
70	Comorbidities associated with higher von Willebrand factor (<scp>VWF</scp>) levels may explain the ageâ€related increase of <scp>VWF</scp> in von Willebrand disease. British Journal of Haematology, 2018, 182, 93-105.	1.2	39
71	Hemostatic efficacy of pathogen-inactivated vs untreated platelets: a randomized controlled trial. Blood, 2018, 132, 223-231.	0.6	71
72	Thrombocytopenia and bleeding in myelosuppressed transfusion-dependent patients: a simulation study exploring underlying mechanisms. Clinical Epidemiology, 2018, Volume 10, 401-411.	1.5	1

#	Article	IF	CITATIONS
73	Management of postpartum hemorrhage: how to improve maternal outcomes?. Journal of Thrombosis and Haemostasis, 2018, 16, 1523-1534.	1.9	27
74	Identification of Self-Limiting Pediatric Immune Thrombocytopenia at Diagnosis. Blood, 2018, 132, 1145-1145.	0.6	0
75	Storage medium of platelet transfusions and the risk of transfusionâ€ŧransmitted bacterial infections. Transfusion, 2017, 57, 657-660.	0.8	14
76	Intensity of factor VIII treatment and the development of inhibitors in nonâ€severe hemophilia A patients: results of the INSIGHT case–control study. Journal of Thrombosis and Haemostasis, 2017, 15, 1422-1429.	1.9	28
77	Relative risk of hemorrhage during pregnancy in patients with brain arteriovenous malformations. International Journal of Stroke, 2017, 12, 741-747.	2.9	22
78	Long-term impact of joint bleeds in von Willebrand disease: a nested case-control study. Haematologica, 2017, 102, 1486-1493.	1.7	24
79	Application and comparison of the FADES, MADIT, and SHFM-D risk models for risk stratification of prophylactic implantable cardioverter-defibrillator treatment. Europace, 2017, 19, 72-80.	0.7	11
80	Mortality caused by intracranial bleeding in nonâ€severe hemophilia A patients. Journal of Thrombosis and Haemostasis, 2017, 15, 1115-1122.	1.9	19
81	Plasma levels of plasminogen activator inhibitorâ€1 and bleeding phenotype in patients with von Willebrand disease. Haemophilia, 2017, 23, 437-443.	1.0	6
82	Treatments for hematologic malignancies in contrast to those for solid cancers are associated with reduced red cell alloimmunization. Haematologica, 2017, 102, 52-59.	1.7	26
83	Variation in baseline factor VIII concentration in a retrospective cohort of mild/moderate hemophilia A patients carrying identical F8 mutations. Journal of Thrombosis and Haemostasis, 2017, 15, 246-254.	1.9	24
84	Association of Blood Transfusion From Female Donors With and Without a History of Pregnancy With Mortality Among Male and Female Transfusion Recipients. JAMA - Journal of the American Medical Association, 2017, 318, 1471.	3.8	59
85	Effect of solvent/detergentâ€ŧreated pooled plasma on fibrinolysis in reconstituted whole blood. Transfusion, 2017, 57, 2381-2389.	0.8	3
86	Comparing transfusion reaction rates for various plasma types: a systematic review and metaâ€analysis/regression. Transfusion, 2017, 57, 2104-2114.	0.8	32
87	Does a Platelet Transfusion Independently Affect Bleeding and Adverse Outcomes in Cardiac Surgery?. Anesthesiology, 2017, 126, 441-449.	1.3	30
88	Chronic use of low-dose aspirin is not associated with lower bone mineral density in the general population. International Journal of Cardiology, 2017, 244, 298-302.	0.8	10
89	Storage time of platelet concentrates and allâ€cause bacteremia in hematologic patients. Transfusion, 2017, 57, 2096-2103.	0.8	3
90	Viscoelastometric testing, fibrinogen and transfusion during post-partum haemorrhage. British Journal of Anaesthesia, 2017, 119, 352-353.	1.5	2

#	Article	IF	CITATIONS
91	The effect of tranexamic acid on blood loss and maternal outcome in the treatment of persistent postpartum hemorrhage: A nationwide retrospective cohort study. PLoS ONE, 2017, 12, e0187555.	1.1	24
92	Third trimester screening for alloimmunisation in <scp>R</scp> hcâ€negative pregnant women: evaluation of the <scp>D</scp> utch national screening programme. BJOG: an International Journal of Obstetrics and Gynaecology, 2016, 123, 955-963.	1,1	16
93	Dissecting intensive treatment as risk factor for inhibitor development in haemophilia. Haemophilia, 2016, 22, e241-4.	1.0	3
94	A study protocol for a randomised controlled trial evaluating clinical effects of platelet transfusion products: the Pathogen Reduction Evaluation and Predictive Analytical Rating Score (PREPAReS) trial. BMJ Open, 2016, 6, e010156.	0.8	22
95	Red cell alloimmunisation in patients with different types of infections. British Journal of Haematology, 2016, 175, 956-966.	1.2	50
96	Early occurrence of red blood cell alloimmunization in patients with sickle cell disease. American Journal of Hematology, 2016, 91, 763-769.	2.0	48
97	Red-blood-cell alloimmunisation in relation to antigens' exposure and their immunogenicity: a cohort study. Lancet Haematology,the, 2016, 3, e284-e292.	2.2	83
98	Intraoperative Anemia and Single Red Blood Cell Transfusion During Cardiac Surgery: An Assessment of Postoperative Outcome Including Patients Refusing Blood Transfusion. Journal of Cardiothoracic and Vascular Anesthesia, 2016, 30, 363-372.	0.6	24
99	Continuing use of the terms prospective and retrospective and quality of reporting of observational studies: time to update the STROBE guideline?. International Journal of Epidemiology, 2016, 45, 587-589.	0.9	1
100	Postpartum Circulating Markers of Inflammation and the Systemic Acute-Phase Response After Early-Onset Preeclampsia. Hypertension, 2016, 67, 404-414.	1.3	41
101	Hospital-acquired anemia: the contribution of diagnostic blood loss. Journal of Thrombosis and Haemostasis, 2015, 13, 1157-1159.	1.9	13
102	CLEC4M and STXBP5 gene variations contribute to vonÂWillebrand factor level variation in von Willebrand disease. Journal of Thrombosis and Haemostasis, 2015, 13, 956-966.	1.9	45
103	von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease. Blood, 2015, 125, 3006-3013.	0.6	62
104	Bleeding spectrum in children with moderate or severe von <scp>W</scp> illebrand disease: <scp>R</scp> elevance of pediatricâ€specific bleeding. American Journal of Hematology, 2015, 90, 1142-1148.	2.0	46
105	Thrombin generation and low-molecular-weight heparin prophylaxis in pregnant women with thrombophilia. Thrombosis and Haemostasis, 2015, 113, 283-289.	1.8	6
106	Transfusionâ€related acute lung injury not a twoâ€hit, but a multicausal model. Transfusion, 2015, 55, 953-960.	0.8	22
107	Time-Dependent Effects of Aspirin on Blood Pressure and Morning Platelet Reactivity. Hypertension, 2015, 65, 743-750.	1.3	62
108	Clinical practice of platelet transfusions in haematoâ€oncology. Vox Sanguinis, 2015, 109, 91-94.	0.7	6

#	Article	IF	CITATIONS
109	Risk of Myocardial Infarction Immediately After Alcohol Consumption. Epidemiology, 2015, 26, 143-150.	1.2	26
110	Joint bleeds in von Willebrand disease patients have significant impact on quality of life and joint integrity: a crossâ€sectional study. Haemophilia, 2015, 21, e185-92.	1.0	43
111	Intensive red blood cell transfusions and risk of alloimmunization. Transfusion, 2014, 54, 278-284.	0.8	9
112	Effect of aspirin intake at bedtime versus on awakening on circadian rhythm of platelet reactivity. Thrombosis and Haemostasis, 2014, 112, 1209-1218.	1.8	58
113	Effect of von <scp>W</scp> illebrand factor on inhibitor eradication in patients with severe haemophilia <scp>A</scp> : a systematic review. British Journal of Haematology, 2014, 166, 485-495.	1.2	31
114	Observational etiologic research. Transfusion, 2014, 54, 12-16.	0.8	4
115	Tolerance of intraoperative hemoglobin decrease during cardiac surgery. Transfusion, 2014, 54, 2696-2704.	0.8	32
116	Secondâ€generation recombinant factor <scp>VIII</scp> and inhibitor risk: interpretation of <scp>RODIN</scp> study findings and implications for patients with haemophilia A. Haemophilia, 2014, 20, e171-4.	1.0	15
117	Ovarian insufficiency and pubertal development after hematopoietic stem cell transplantation in childhood. Pediatric Blood and Cancer, 2014, 61, 2048-2053.	0.8	36
118	Effect of βâ€blockers on platelet aggregation: a systematic review and metaâ€analysis. British Journal of Clinical Pharmacology, 2014, 78, 940-949.	1.1	32
119	Immunosuppressants and alloimmunization against red blood cell transfusions. Transfusion, 2014, 54, 1981-1987.	0.8	58
120	Neonatal thrombocytopenia: etiology, management and outcome. Expert Review of Hematology, 2014, 7, 387-395.	1.0	54
121	Rotem in postpartum hemorrhage. Blood, 2014, 124, 1700-1701.	0.6	7
122	Risk factors for complications in donors at first and repeat whole blood donation: a cohort study with assessment of the impact on donor return. Blood Transfusion, 2014, 12 Suppl 1, s28-36.	0.3	8
123	Clinical outcomes after peripheral blood stem cell donation by related donors: a Dutch singleâ€center cohort study. Transfusion, 2013, 53, 96-103.	0.8	19
124	Identification of 18 High Risk F8 Mutations for Inhibitor Development in 2,700 Non-Severe Hemophilia A Patients. Tijdschrift Voor Kindergeneeskunde, 2013, 81, 38-38.	0.0	0
125	Association Vs Causality in Transfusion Medicine: Understanding Multivariable Analysis in Prediction Vs Etiologic Research. Transfusion Medicine Reviews, 2013, 27, 74-81.	0.9	13
126	Storage Time of Red Blood Cells and Mortality of Transfusion Recipients. Transfusion Medicine Reviews, 2013, 27, 36-43.	0.9	56

#	Article	IF	CITATIONS
127	Observational etiologic research. Transfusion, 2013, 54, n/a-n/a.	0.8	7
128	Posttransfusion platelet increments after different platelet products in neonates: a retrospective cohort study. Transfusion, 2013, 53, 3100-3109.	0.8	8
129	Observational etiologic research. Transfusion, 2013, 53, 2606-2608.	0.8	4
130	Effect of storage of red blood cells on alloimmunization. Transfusion, 2013, 53, 2795-2800.	0.8	24
131	Observational etiologic research. Transfusion, 2013, 53, 3048-3051.	0.8	1
132	Thrombin Generation and Low Molecular Weight Heparin Prophylaxis In Pregnant Women With Thrombophilia. Blood, 2013, 122, 1140-1140.	0.6	0
133	Clinical prediction model for death prior to appropriate therapy in primary prevention implantable cardioverter defibrillator patients with ischaemic heart disease: the FADES risk score. Heart, 2012, 98, 872-877.	1.2	49
134	Risk Factors for Alloimmunisation after red blood Cell Transfusions (R-FACT): a case cohort study. BMJ Open, 2012, 2, e001150.	0.8	26
135	Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease. Thrombosis and Haemostasis, 2012, 108, 683-692.	1.8	87
136	Redâ€bloodâ€cell alloimmunization and number of redâ€bloodâ€cell transfusions. Vox Sanguinis, 2012, 102, 144-149.	0.7	83
137	Storage time of blood products and transfusionâ€related acute lung injury. Transfusion, 2012, 52, 658-667.	0.8	44
138	A comparison of volumeâ€reduced versus standard HLA/HPA–matched apheresis platelets in alloimmunized adult patients. Transfusion, 2012, 52, 742-751.	0.8	14
139	Alloâ€exposure status and leucocyte antibody positivity of blood donors show a similar relation with TRALI. Transfusion Medicine, 2012, 22, 128-132.	0.5	1
140	Mortality after transfusions, relation to donor sex. Vox Sanguinis, 2011, 101, 221-229.	0.7	41
141	Maleâ€only freshâ€frozen plasma for transfusionâ€related acute lung injury prevention: beforeâ€andâ€after comparative cohort study. Transfusion, 2011, 51, 1278-1283.	0.8	65
142	Alloexposed blood donors and transfusionâ€related acute lung injury: a caseâ€referent study. Transfusion, 2011, 51, 2111-2117.	0.8	8
143	Impact of von Willebrand disease on healthâ€related quality of life in a pediatric population. Journal of Thrombosis and Haemostasis, 2011, 9, 502-509.	1.9	30
144	Comment on "Effect of storage time of transfused plasma on early and late mortality after coronary artery bypass grafting― Journal of Thoracic and Cardiovascular Surgery, 2011, 142, 473-474.	0.4	2

#	Article	IF	CITATIONS
145	The 5352 A allele of the pro-inflammatory caspase-1 gene predicts late-acquired stent malapposition in STEMI patients treated with sirolimus stents. Heart and Vessels, 2011, 26, 235-241.	0.5	3
146	Asymmetric Dimethylarginine (ADMA) Levels Display a Morning Peak in Patients with Acute Myocardial Infarction. Disease Markers, 2011, 30, 245-252.	0.6	8
147	A solution to the problem of studying blood donor–related risk factors when patients have received multiple transfusions. Transfusion, 2010, 50, 1959-1966.	0.8	11
148	Blood transfusions: good or bad?. Transfusion, 2010, 50, 1181-1183.	0.8	69
149	Female donors and transfusionâ€related acute lung injury. Transfusion, 2010, 50, 2447-2454.	0.8	46
150	Healthâ€related quality of life among adult patients with moderate and severe von Willebrand disease. Journal of Thrombosis and Haemostasis, 2010, 8, 1492-1499.	1.9	75
151	PREDICTION OF MORTALITY RISK IN PRIMARY PREVENTION ICD RECIPIENTS WITH ISCHEMIC HEART DISEASE: AN EASY APPLICABLE RISK SCORE. Journal of the American College of Cardiology, 2010, 55, A14.E133.	1.2	0
152	Assessment of incidence of inhibitors in patients with haemophilia. Haemophilia, 2009, 15, 707-711.	1.0	8
153	Platelet count and the risk for thrombosis and death in the elderly. Journal of Thrombosis and Haemostasis, 2009, 7, 399-405.	1.9	77
154	Myocardial Infarction Occurs with a Similar 24 h Pattern in the 4G/5G Versions of Plasminogen Activator Inhibitor-1. Chronobiology International, 2009, 26, 637-652.	0.9	4
155	The role of donor antibodies in the pathogenesis of transfusionâ€related acute lung injury: a systematic review. Transfusion, 2008, 48, 2167-2176.	0.8	105
156	Social participation of patients with hemophilia in the Netherlands. Blood, 2008, 111, 1811-1815.	0.6	71
157	MISSION!: Optimization of acute and chronic care for patients with acute myocardial infarction. American Heart Journal, 2007, 153, 14.e1-14.e11.	1.2	116
158	Prevalence of persistent platelet reactivity despite use of aspirin: A systematic review. American Heart Journal, 2007, 153, 175-181.	1.2	241
159	Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: A systematic review and meta-analysis. American Heart Journal, 2007, 154, 221-231.	1.2	390
160	Prediction of Findings at Defecography in Patients with Genital Prolapse. Obstetrical and Gynecological Survey, 2006, 61, 96-98.	0.2	0
161	Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study1. Journal of Thrombosis and Haemostasis, 2006, 4, 510-516.	1.9	252
162	How do the prevalences of urogenital symptoms change during pregnancy?. Neurourology and Urodynamics, 2006, 25, 135-139.	0.8	67

#	Article	IF	CITATIONS
163	Prediction of findings at defecography in patients with genital prolapse. BJOG: an International Journal of Obstetrics and Gynaecology, 2005, 112, 1547-1553.	1.1	18
164	Effects of haemophilic arthropathy on health-related quality of life and socio-economic parameters. Haemophilia, 2005, 11, 43-48.	1.0	91
165	Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed. Haemophilia, 2005, 11, 438-443.	1.0	125
166	NO PROTECTIVE EFFECT OF BREASTFEEDING ON INHIBITOR FORMATION IN SEVERE HEMOPHILIA. Pediatric Hematology and Oncology, 2005, 22, 575-580.	0.3	6
167	Euthanasia and Depression: A Prospective Cohort Study Among Terminally Ill Cancer Patients. Journal of Clinical Oncology, 2005, 23, 6607-6612.	0.8	117
168	Risk factors in the elderly. , 2005, , 606-628.		1
169	Do prothrombotic factors influence clinical phenotype of severe haemophilia? A review of the literature. Thrombosis and Haemostasis, 2004, 92, 305-310.	1.8	65
170	Functional consequences of haemophilia in adults: the development of the Haemophilia Activities List. Haemophilia, 2004, 10, 565-571.	1.0	105
171	Influenza and pneumococcal vaccination as a model to assess C-reactive protein response to mild inflammation. Vaccine, 2004, 23, 362-365.	1.7	43
172	Functional tasks exercise versus resistance exercise to improve daily function in older women: A feasibility study. Archives of Physical Medicine and Rehabilitation, 2004, 85, 1952-1961.	0.5	66
173	Thirty years of hemophilia treatment in the Netherlands, 1972-2001. Blood, 2004, 104, 3494-3500.	0.6	101
174	Incidence and Outcome of Discontinuation of Prophylactic Treatment among Young Adults with Severe Hemophilia Blood, 2004, 104, 3086-3086.	0.6	5
175	The 4G5G polymorphism in the gene for PAI-1 and the circadian oscillation of plasma PAI-1. Blood, 2003, 101, 1841-1844.	0.6	53
176	Age at first treatment and immune tolerance to factor VIII in severe hemophilia. Thrombosis and Haemostasis, 2003, 89, 475-479.	1.8	108
177	Age at first treatment and immune tolerance to factor VIII in severe hemophilia. Thrombosis and Haemostasis, 2003, 89, 475-9.	1.8	15
178	Association between joint bleeds and pettersson scores in severe haemophilia. Acta Radiologica, 2002, 43, 528-532.	0.5	31
179	Activation of coagulation and fibrinolytic system and thrombotic tendency. Lancet, The, 2002, 360, 801-802.	6.3	2
180	Does plasma fibrinogen increase thrombotic tendency?. European Journal of Clinical Investigation, 2002, 32, 721-722.	1.7	2

11

#	Article	IF	CITATIONS
181	Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy. Haemophilia, 2001, 7, 446-452.	1.0	107
182	Does mode of hysterectomy influence micturition and defecation?. Acta Obstetricia Et Gynecologica Scandinavica, 2001, 80, 945-51.	1.3	24
183	Does mode of hysterectomy influence micturition and defecation?. Acta Obstetricia Et Gynecologica Scandinavica, 2001, 80, 945-951.	1.3	48
184	Urinary incontinence after hysterectomy. Lancet, The, 2000, 356, 2012.	6.3	5
185	Fibrinolytic Activity in Peripheral Atherosclerosis in the Elderly. Thrombosis and Haemostasis, 1999, 81, 275-280.	1.8	14
186	Response to Activated Protein C and Cerebrovascular Disease. Annals of Internal Medicine, 1997, 126, 833.	2.0	0
187	Reduced Response to Activated Protein C Is Associated with Increased Risk for Cerebrovascular Disease. Annals of Internal Medicine, 1996, 125, 265.	2.0	107
188	Predicting organ functioning with and without blood transfusion in critically ill patients with anemia. Transfusion, 0, , .	0.8	1